NCT05339386View on ClinicalTrials.gov

Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension

Active, not recruitingOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Hyperpolarized Xe129

Lung MRI using gaseous contrast agent hyperpolarized 129Xe.

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

University of Kansas Medical Center

OTHER